TheraRadar
Data updated: May 26, 2026

AMRIX (cyclobenzaprine hydrochloride)

Musculoskeletal Approved 2007-02-01

Amrix helps patients with muscle spasms caused by sudden, painful musculoskeletal conditions. It is used as an addition to rest and physical therapy to help improve pain, tenderness, and physical movement. This medication is intended for short-term use, typically up to three weeks, as these types of muscle issues usually resolve quickly. It is not used for spasms caused by central nervous system diseases like cerebral palsy.

How AMRIX Works

This medication works by acting primarily on the brain stem within the central nervous system to reduce tonic motor activity. It targets the alpha and gamma motor systems to relieve spasms without directly affecting muscle tissue or interfering with normal muscle function. Its effects are similar to those of tricyclic antidepressants, influencing the nervous system to decrease skeletal muscle hyperactivity.

1
Indication
--
Phase 3 Trials
19
Years on Market

Details

Status
Prescription
First Approved
2007-02-01
Routes
ORAL
Dosage Forms
CAPSULE, EXTENDED RELEASE

Companies

Active Ingredient: CYCLOBENZAPRINE HYDROCHLORIDE

AMRIX Approval History

2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
18 FDA actions from 2007 to 2024
Apr 2024 SUPPL
Label · Labeling
Apr 2019 SUPPL
Label · Labeling
May 2016 SUPPL
Label · Labeling

What AMRIX Treats

2 indications

AMRIX is approved for 2 conditions since its original approval in 2007. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Muscle Spasm
  • Musculoskeletal Condition
Source: FDA Label

AMRIX Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Indication competitors

1

Same indication, different mechanism — what else might this patient receive?

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

Drugs Similar to AMRIX

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

DIASTAT ACUDIAL
DIAZEPAM
1 shared
BAUSCH
Shared indications:
Muscle Spasm
DIAZEPAM INTENSOL
DIAZEPAM
1 shared
Hikma
Shared indications:
Muscle Spasm
📋

Clinical Trial Registry

1 trials
Trial Sponsor ID Phase Status Title
NCT01151787 CEPH03242010 Ph 3 terminated Efficacy and Safety of Cyclobenzaprine Hydrochloride Extended Release for the Treatment of Chronic Migraine
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

AMRIX FDA Label Details

Indications & Usage

FDA Label (PDF)

AMRIX is indicated for the treatment of Muscle Spasm; Musculoskeletal Condition.

Track AMRIX with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.